Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
5
×
new york blog main
biotech
boston top stories
national top stories
new york top stories
san diego blog main
san francisco blog main
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
regeneron pharmaceuticals
san diego top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alirocumab
alnylam pharmaceuticals
bluebird bio
fda
gene therapy
medicare
rna interference
vertex pharmaceuticals
alex azar
ambys medicines
american patients first
What
drug
5
×
long
5
×
prices
awaited
data
details
drugs
house
lower
medicines
plan
afternoon
ago
alnylam
anathema
anticipated
aren’t
based
bio
biotechs
blueprint
cholesterol
considering
cost
cut
democrat
developers
diseases
dyne
early
elements
evidence
expected
experimental
eyes
fda
gene
genetic
having
heart
Language
unset
Current search:
drug
×
" national blog main "
×
long
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
6 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details